The effect of doxofylline in asthma and COPD.
Asthma
COPD
Doxofylline
Methylxanthines
Theophylline
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
18
11
2019
accepted:
17
02
2020
pubmed:
26
2
2020
medline:
22
10
2020
entrez:
26
2
2020
Statut:
ppublish
Résumé
Theophylline is still one of the most widely prescribed drugs for the treatment of asthma and COPD in developing countries because the majority of asthma and COPD medicines are largely unavailable and also because it is a cheap option. In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. In order to overcome the problems posed by theophylline, other xanthines have been developed. Doxofylline is a newer generation xanthine with both bronchodilating and anti-inflammatory activities and for this reason it has been called "novofylline". It differs substantially from theophylline at the pharmacological level. Clinical studies have shown substantial differences between doxofylline and theophylline. In particular, efficacy/safety profile of doxofylline is better than that of theophylline.
Identifiants
pubmed: 32094104
pii: S0954-6111(20)30044-5
doi: 10.1016/j.rmed.2020.105904
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Bronchodilator Agents
0
Theophylline
C137DTR5RG
doxofylline
MPM23GMO7Z
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
105904Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MC has participated as an advisor in scientific meetings sponsored by ABC Farmaceutici and Mundipharma Bangladesh that manufacture and sell medicinal products containing doxofylline; he is a consultant to ABC Farmaceutici. MGM has participated as an advisor in scientific meetings sponsored by ABC Farmaceutici.